KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and INVO Bioscience (NASDAQ:INVO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Earnings & Valuation
This table compares KORU Medical Systems and INVO Bioscience”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $31.99 million | 5.75 | -$13.74 million | ($0.25) | -16.04 |
| INVO Bioscience | $5.77 million | 0.63 | -$8.03 million | N/A | N/A |
INVO Bioscience has lower revenue, but higher earnings than KORU Medical Systems.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 0 | 0 | 3 | 1 | 3.25 |
| INVO Bioscience | 0 | 0 | 0 | 0 | 0.00 |
KORU Medical Systems presently has a consensus price target of $4.13, indicating a potential upside of 2.87%. Given KORU Medical Systems’ stronger consensus rating and higher possible upside, research analysts clearly believe KORU Medical Systems is more favorable than INVO Bioscience.
Institutional & Insider Ownership
58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 25.6% of KORU Medical Systems shares are owned by company insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares KORU Medical Systems and INVO Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -37.42% | -24.60% | -16.87% |
| INVO Bioscience | -122.79% | N/A | -36.94% |
Risk and Volatility
KORU Medical Systems has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Summary
KORU Medical Systems beats INVO Bioscience on 10 of the 13 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About INVO Bioscience
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
